Brief: Pacira Signs Exclusive License With AmacaThera For Long-Acting Analgesic For Postsurgical Pain Relief
04/11/2025 12:33
Nov 4 (Reuters) - Pacira Biosciences Inc PCRX.O: PACIRA BIOSCIENCES ENTERS EXCLUSIVE LICENSE AGREEMENT WITH AMACATHERA FOR ITS NOVEL LONG-ACTING ANALGESIC FOR POSTSURGICAL PAIN CONTROL PACIRA BIOSCIENCES INC - AMACATHERA TO RECEIVE $5 MILLION UPFRONT PAYMENT PACIRA BIOSCIENCES INC - PHASE 2 PROGRAM FOR AMT-143 EXPECTED TO BEGIN IN 2026 Source text: ID:nGNXbqfk3w Further company coverage: PCRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pacira BioSciences
See all newsUS STOCKS ON THE MOVE-Palantir, Haemonetics
U.S. STOCKS ON THE MOVE-Palantir, Haemonetics, Starbucks
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal
Brief: Viatris - Pacira To Pay Viatris $62 Million Termination Fee Under Specified Circumstances
Pacira BioSciences jumps on $1.65 billion Viatris buyout deal